Osteoprotegerin protects against muscular dystrophy

Area of Science:

• Bone Biology and Musculoskeletal Health
• Cellular Signaling and Disease Pathophysiology

Background:

• Osteoporosis and skeletal muscle atrophy share associations, but the underlying regulatory pathways remain unclear.
• Osteoclast differentiation and bone remodeling are primarily regulated by the Receptor Activator of NF-κB (RANK)/RANK Ligand (RANKL)/osteoprotegerin (OPG) system.

Purpose of the Study:

• To investigate the role of osteoprotegerin in skeletal muscle.
• To explore the therapeutic potential of osteoprotegerin in muscle diseases and osteoporosis.

Main Methods:

• Demonstrated that muscle cells can produce and secrete osteoprotegerin.
• Administered recombinant osteoprotegerin-Fc to dystrophic mdx mice.

Main Results:

• Recombinant osteoprotegerin-Fc treatment mitigated muscle force loss in a dose-dependent manner.
• Osteoprotegerin preserved muscle integrity, particularly in fast-twitch extensor digitorum longus muscles.
• Identified osteoprotegerin as a novel protector of muscle integrity.

Conclusions:

• Osteoprotegerin plays a protective role in skeletal muscle.
• Osteoprotegerin represents a potential therapeutic target for muscular diseases and osteoporosis.